Download the app
App StorePlay Store
Beige
Login
← All tags

generic drugs

Alembic Pharma secures USFDA tentative nod for generic Darolutamide prostate cancer tablets

Alembic Pharma secures USFDA tentative nod for generic Darolutamide prostate cancer tablets

Alembic Pharmaceuticals has received USFDA tentative approval for its generic Darolutamide tablets used in prostate cancer treatment. The approval applies to the 300 mg strength, positioning Alembic’s product as a generic equivalent to Nubeqa Tablets. With significant demand expected for this category, the company could gain momentum as it moves toward final commercialization.

Summarised by Beize from a story on The Economic Times on 14 May 2026
Generic semaglutide prices in India may crash by half with new brands and lower raw costs

Generic semaglutide prices in India may crash by half with new brands and lower raw costs

Generic semaglutide in India is expected to get dramatically cheaper, with prices likely to fall by more than half in the coming months. The drop is linked to the entry of smaller brands and a steep decline in raw material costs. A one month dose could fall to as low as ₹500, potentially widening access to the popular weight-loss drug.

Summarised by Beize from a story on The Economic Times on 13 May 2026

Your news, in seconds

App StorePlay Store
Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s Laboratories has received market authorization from Health Canada for its generic semaglutide injection, becoming the first company approved for the diabetes therapy in Canada. The Bengaluru-based pharma is now preparing a launch to expand access for patients who rely on the treatment, potentially easing pressure on medication availability and costs.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026
Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Generic semaglutide rush hits India as Novo Nordisk patent fallout reshapes obesity drug prices

Generic semaglutide rush hits India as Novo Nordisk patent fallout reshapes obesity drug prices

India’s weight-loss drug market is rapidly shifting as generic semaglutide becomes available after Novo Nordisk’s patent loss. The cheaper alternatives are already pressuring Eli Lilly’s sales while unlocking a surge in demand. With multiple Indian drugmakers racing to launch affordable options, the country’s obesity-treatment landscape is entering a new, more price-accessible phase.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Alembic Pharma wins USFDA nod for generic methotrexate injection for cancer and arthritis

Alembic Pharma wins USFDA nod for generic methotrexate injection for cancer and arthritis

Alembic Pharmaceuticals has received USFDA final approval for its generic methotrexate injection, a widely used medicine for multiple cancers and inflammatory conditions. The regulator greenlit key dosage formats and confirmed therapeutic equivalence to the reference Hospira product, clearing the way for Alembic to market the injectable in the US for cancers and conditions like rheumatoid arthritis and severe psoriasis.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
Lupin launches generic dapagliflozin and metformin tablets in the US after FDA approval

Lupin launches generic dapagliflozin and metformin tablets in the US after FDA approval

Lupin has launched generic anti-diabetic tablets in the United States—dapagliflozin and metformin hydrochloride extended-release—after receiving FDA approval. The company says its product is bioequivalent to Xigduo XR, positioning the launch as a potential new option for diabetes patients seeking effective treatment in the US market.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
US market prospects for Indian pharma brighten as shortages and new generics reshape profits

US market prospects for Indian pharma brighten as shortages and new generics reshape profits

Indian pharma’s US outlook has improved after years of pressure from price erosion and compliance hurdles. Drug shortages have temporarily slowed price erosion, while launches of key generic drugs have helped companies regain footing. Yet the real question is sustainability: will the same conditions hold, or will competition and supply normalization bring renewed margin stress?

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play